pdf   xlsx method abbreviations

lung cancer : non small cell (NSCLC), ... versus placebo, meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.40 [0.09, 1.80]< 10%1 study (1/-)88.3 %NAnot evaluable crucial-
RFS/DFS 0.20 [0.14, 0.29]< 10%1 study (1/-)100.0 %NAnot evaluable important-
events or deaths (EFS) 0.17 [0.11, 0.26]< 10%1 study (1/-)100.0 %NAnot evaluable non important-

safety endpoints 00

AE (any grade) 4.97 [2.28, 10.85]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
AE leading to death (grade 5) 0.51 [0.02, 15.20]< 10%1 study (1/-)65.0 %NAnot evaluable non important-
AE leading to treatment discontinuation (any grade) 4.11 [2.01, 8.40]< 10%1 study (1/-)0.0 %NAnot evaluable non important-

AE (grade 3-4) endpoints 00

Cough AE (grade 3-4) 1.02 [0.02, 51.45]< 10%1 study (1/-)49.7 %NAnot evaluable non important-
Decreased appetite AE (grade 3-4) 4.09 [0.18, 91.02]< 10%1 study (1/-)19.0 %NAnot evaluable non important-
Dermatitis acneiform AE (grade 3-4) 1.02 [0.02, 51.45]< 10%1 study (1/-)49.7 %NAnot evaluable non important-
Diarrhoea AE (grade 3-4) 8.32 [1.03, 66.86]< 10%1 study (1/-)2.4 %NAnot evaluable non important-
Dry skin AE (grade 3-4) 2.04 [0.07, 60.97]< 10%1 study (1/-)34.3 %NAnot evaluable non important-
Pruritus AE (grade 3-4) 1.02 [0.02, 51.45]< 10%1 study (1/-)49.7 %NAnot evaluable non important-
Stomatitis AE (grade 3-4) 12.42 [0.69, 223.20]< 10%1 study (1/-)4.5 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons